{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:09:39Z","timestamp":1765202979688,"version":"3.46.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98710","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:06:55Z","timestamp":1765202815000},"source":"Crossref","is-referenced-by-count":0,"title":["Pooled Incidence of Heparin-Induced Thrombocytopenia and Anti-Platelet Factor 4 Antibody Formation Among Adults: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Anudeep","family":"Devarapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya","family":"Rachamanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounika","family":"Singampalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Hullur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.143","article-title":"How I diagnose and manage HIT","volume":"2011","author":"Warkentin TE","year":"2011","unstructured":"Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011, 2011:143-9. 10.1182\/asheducation-2011.1.143","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp052967","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"355","author":"Arepally GM","year":"2006","unstructured":"Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006, 355:809-17. 10.1056\/NEJMcp052967","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher A","year":"2015","unstructured":"Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015, 373:252-61. 10.1056\/NEJMcp1411910","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-580894","article-title":"Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis","volume":"125","author":"Padmanabhan A","year":"2015","unstructured":"Padmanabhan A, Jones CG, Bougie DW, Curtis BR, McFarland JG, Wang D, Aster RH. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood. 2015, 125:155-61. 10.1182\/blood-2014-06-580894","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management","volume":"25","author":"Hogan M","year":"2020","unstructured":"Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med. 2020, 25:160-73. 10.1177\/1358863X19898253","journal-title":"Vasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed I","year":"2007","unstructured":"Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007, 83:575-82. 10.1136\/pgmj.2007.059188","journal-title":"Postgrad Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13533","article-title":"The association of anti-platelet factor 4\/heparin antibodies with early and delayed thromboembolism after cardiac surgery","volume":"15","author":"Welsby IJ","year":"2017","unstructured":"Welsby IJ, Krakow EF, Heit JA, et al.. The association of anti-platelet factor 4\/heparin antibodies with early and delayed thromboembolism after cardiac surgery. J Thromb Haemost. 2017, 15:57-65. 10.1111\/jth.13533","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel N","year":"2005","unstructured":"Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005, 106:2710-15. 10.1182\/blood-2005-04-1546","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow N","year":"2010","unstructured":"Lubenow N, Hinz P, Thomaschewski S, et al.. The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010, 115:1797-803. 10.1182\/blood-2009-07-231506","journal-title":"Blood"},{"key":"ref10","article-title":"Heparin-induced thrombocytopenia","author":"Nicolas D","year":"2023","unstructured":"Nicolas D, Nicolas S, Hodgens A, et al.. Heparin-induced thrombocytopenia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref11","unstructured":"The R project for statistical computing. (2024). Accessed. December 6, 2025: https:\/\/www.R-project.org."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1076029611398121","article-title":"Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin","volume":"17","author":"Griffin JW","year":"2011","unstructured":"Griffin JW, Hopkinson WJ, Lassen MR, Thethi I, Litinas E, Fareed J. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin. Clin Appl Thromb Hemost. 2011, 17:567-71. 10.1177\/1076029611398121","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04402.x","article-title":"Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry","volume":"9","author":"Falvo N","year":"2011","unstructured":"Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jim\u00e9nez-Gil M, Di Micco P, Monreal M. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011, 9:1761-8. 10.1111\/j.1538-7836.2011.04402.x","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-22","article-title":"IgG-class anti-PF4\/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics","volume":"12","author":"Motokawa S","year":"2011","unstructured":"Motokawa S, Torigoshi T, Maeda Y, et al.. IgG-class anti-PF4\/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord. 2011, 12:22. 10.1186\/1471-2474-12-22","journal-title":"BMC Musculoskelet Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651620","article-title":"Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4\/heparin antibody formation after orthopedic surgery","volume":"127","author":"Bito S","year":"2016","unstructured":"Bito S, Miyata S, Migita K, et al.. Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4\/heparin antibody formation after orthopedic surgery. Blood. 2016, 127:1036-43. 10.1182\/blood-2015-06-651620","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-014-1105-2","article-title":"Prevalence and clinical implications of anti-PF4\/heparin antibodies in intensive care patients: a prospective observational study","volume":"39","author":"Selleng S","year":"2015","unstructured":"Selleng S, Selleng K, Friesecke S, et al.. Prevalence and clinical implications of anti-PF4\/heparin antibodies in intensive care patients: a prospective observational study. J Thromb Thrombolysis. 2015, 39:60-7. 10.1007\/s11239-014-1105-2","journal-title":"J Thromb Thrombolysis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14317","article-title":"Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer","volume":"16","author":"Van Matre ET","year":"2018","unstructured":"Van Matre ET, Reynolds PM, MacLaren R, et al.. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost. 2018, 16:2492-500. 10.1111\/jth.14317","journal-title":"J Thromb Haemost"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.029","article-title":"Is the incidence trend of heparin-induced thrombocytopenia decreased by the increased use of low-molecular-weight-heparin?","volume":"7","author":"Al-Eidan FA","year":"2015","unstructured":"Al-Eidan FA. Is the incidence trend of heparin-induced thrombocytopenia decreased by the increased use of low-molecular-weight-heparin?. Mediterr J Hematol Infect Dis. 2015, 7:e2015029. 10.4084\/MJHID.2015.029","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618165","article-title":"Combination of 4Ts score and PF4\/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study","volume":"126","author":"Linkins LA","year":"2015","unstructured":"Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4\/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015, 126:597-603. 10.1182\/blood-2014-12-618165","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012782","article-title":"Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia","volume":"8","author":"Nilius H","year":"2024","unstructured":"Nilius H, Hamzeh-Cognasse H, Hastings J, et al.. Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia. Blood Adv. 2024, 8:2825-34. 10.1182\/bloodadvances.2024012782","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2450\/2020.0120-20","article-title":"Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay","volume":"19","author":"\u017deleznik K","year":"2021","unstructured":"\u017deleznik K, Ro\u017eman P, Kocjan E, Mali\u010dev E. Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay. Blood Transfus. 2021, 19:77-84. 10.2450\/2020.0120-20","journal-title":"Blood Transfus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia: a comprehensive clinical review","volume":"67","author":"Salter BS","year":"2016","unstructured":"Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, Fischer GW. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol. 2016, 67:2519-32. 10.1016\/j.jacc.2016.02.073","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7385","article-title":"Heparin-induced thrombocytopenia: pathophysiology, diagnosis and management","volume":"12","author":"Patriarcheas V","year":"2020","unstructured":"Patriarcheas V, Pikoulas A, Kostis M, Charpidou A, Dimakakos E. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and management. Cureus. 2020, 12:e7385. 10.7759\/cureus.7385","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040683","article-title":"Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management","volume":"10","author":"Marchetti M","year":"2021","unstructured":"Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021, 10:683. 10.3390\/jcm10040683","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1177\/1358836X0100600208","article-title":"Heparin-induced thrombocytopenia: natural history, diagnosis, and management","volume":"6","author":"Deitcher SR","year":"2001","unstructured":"Deitcher SR, Carman TL. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med. 2001, 6:113-19.","journal-title":"Vasc Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.15","article-title":"Relationship between the 4Ts scoring system and the antiplatelet factor 4\/heparin antibodies test in critically ill patients","volume":"1","author":"Matsumura Y","year":"2014","unstructured":"Matsumura Y, Nakada TA, Oda S. Relationship between the 4Ts scoring system and the antiplatelet factor 4\/heparin antibodies test in critically ill patients. Acute Med Surg. 2014, 1:37-44. 10.1002\/ams2.15","journal-title":"Acute Med Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443250-pooled-incidence-of-heparin-induced-thrombocytopenia-and-anti-platelet-factor-4-antibody-formation-among-adults-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:06:58Z","timestamp":1765202818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443250-pooled-incidence-of-heparin-induced-thrombocytopenia-and-anti-platelet-factor-4-antibody-formation-among-adults-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.98710","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}